Regulatory Submission Translation Services

Why is accurate translation crucial for regulatory submissions?

What are the different types of regulatory submission translations?

There are six principal types of regulatory submission translation: CTD/eCTD modules, clinical trial documentation, marketing authorisation dossiers, medical device technical files, pharmacovigilance content and labelling/patient information. Each document type carries a distinct linguistic risk profile, and each is matched to a specific QA workflow inside the ISO 17100 audit trail. Coverage extends across 150+ languages, including all 24 EU official languages, so that every jurisdiction in a global development programme is served from a single, consistent terminology source.

How do CTD and eCTD module translations work?

CTD and eCTD translation covers all five modules: Module 1 (regional administrative), Module 2 (summaries), Module 3 (quality), Module 4 (non-clinical) and Module 5 (clinical), each with a different linguistic risk profile. Module 1 administrative content accepts AI-assisted drafting with full human post-editing. Modules 3–5 require full ISO 17100 TEP with MedDRA and EDQM Standard Term alignment, because a mistranslated specification, clinical endpoint or safety statement carries direct regulatory consequence. Translation memory built during Module 2 summaries is reused across Modules 3–5 to enforce terminology consistency throughout the dossier.

What clinical trial documents require translation?

Clinical trial translation covers protocols, investigator brochures (IBs), informed consent forms (ICFs), patient-facing questionnaires (COAs and ePROs), IMPDs and site contracts for every country in the study footprint. Informed consent forms and patient outcome instruments pass through linguistic validation, not just TEP, because the regulatory standard for participant-facing content requires cognitive debriefing with target-language patients. Site contracts and investigator agreements are handled under our Legal Translation Services workflow, while protocols and investigator brochures fall under our Medical Translation Services team. The EU Clinical Trial Regulation requires all participant-facing content to be available in the languages the trial subjects speak, making country-level translation a legal obligation rather than a best-practice recommendation.

How are medical device IFUs and technical files translated under EU MDR and IVDR?

EU MDR 2017/745 and IVDR 2017/746 require IFUs, labels, SSCPs and UDI content in the official language or languages of every Member State where the device is placed on the market, covering all 24 EU official languages where relevant, with linguistic validation applied to patient-facing content. Northern Ireland retains MDR/IVDR alignment, so devices marketed there follow EU language obligations rather than MHRA English-only rules. Technical file translation work is delivered through our Technical Translation Services team, which is experienced in formatting content to meet notified body and competent authority presentation standards.

What labelling and patient information leaflet translations does the EMA require?

The EMA requires SmPC, PIL and labelling in QRD template format across all 24 EU official languages at Day 210 of the centralised procedure, with each language version checked by the relevant national competent authority during the linguistic review. The marketing authorisation is initially granted in English, French and German; the marketing authorisation holder then supplies translations into every other official EU language before commercialisation in each Member State. Failure to deliver all 24 language versions on time holds up grant of the marketing authorisation, making Day 210 linguistic readiness a critical path item for every centralised procedure.

What pharmacovigilance documents require translation?

Pharmacovigilance translation covers PSURs (periodic safety update reports), DSURs (development safety update reports), ICSR narratives and risk management plans (RMPs). Each of these document types is subject to MedDRA terminology validation to prevent adverse-event misclassification across language versions. ICSR narratives in particular require precise rendering of medical history, suspect drug information and outcome terms, because inconsistency between source and translated narratives can distort signal detection in post-marketing safety surveillance.

Can anyone do a certified translation for regulatory submissions?

No — regulatory submission translations must be produced by linguists who hold ISO 17100 competence, work under a documented quality management system, and can supply CVs and a Certificate of Accuracy on request from an inspector. ISO 17100 defines competence as a relevant translation or language degree combined with at least two years of domain experience, or equivalent demonstrated competence evidenced through a substantial volume of subject-specific work. General language proficiency alone is insufficient; the work demands deep domain expertise in pharmaceutical science, clinical methodology or medical device engineering, depending on the document class. Full details on our Certified Translation Services page.

The regulatory consequence of using an unqualified provider is not merely administrative. A translation produced without a documented TEP workflow and traceable linguist qualifications cannot be defended before a GCP inspector or pharmacovigilance auditor. If that translation forms part of a submitted dossier and the authority raises a linguistic query, the sponsor has no evidence of due diligence to present — and the query can escalate into a deficiency letter, a Refusal to File or, in the worst case, a post-approval safety concern tied to a mislabelled product.

How do you qualify a pharmaceutical translation provider for regulatory submissions?

Qualify a translation partner by verifying five criteria:

1. ISO 17100 certification, verified by certificate number and scope — the scope must explicitly cover pharmaceutical, clinical or medical device translation as applicable.
2. An ISO 9001 quality management system underpinning documentation, version control and audit trails across all projects.
3. Documented translator qualifications — a relevant degree, domain experience and a CV retrievable per project on inspector request.
4. TEP version-control evidence linking every translated segment to the translator, reviser and proofreader who handled it, with timestamps.
5. A signed confidentiality agreement covering all regulatory dossier content shared with linguists and project managers.

What documentation of translator qualifications does a GCP or pharmacovigilance inspector require?

Inspectors require translator CVs, ISO 17100 competence records, signed NDAs, TEP audit trails and terminology sign-off logs, packaged in an inspection-ready evidence file. The evidence pack is produced per procedure and retained for the sponsor’s post-approval lifecycle, including PSUR and RMP updates that are audited retrospectively rather than pre-approved. Because pharmacovigilance inspections frequently cover translation quality for ICSR narratives and risk management plans, the audit trail must extend beyond the initial marketing authorisation into every subsequent document produced under the same product licence.

What are the best practices for streamlining multilingual regulatory submissions?

The five best practices for streamlining multilingual regulatory submissions are:

1. Freeze the source language before translation starts. Any amendment to source content after translation has begun triggers a cascade of re-translation, re-revision and re-proofing across every target language — multiplied by up to 24 EU official languages for a centralised procedure. Source lock is the single most impactful process control available to a regulatory affairs team.
2. Build the termbase before the first module is drafted. A version-controlled termbase aligned to MedDRA preferred terms and EDQM Standard Terms must be in place before translation begins, so that consistency is enforced from the outset rather than retrofitted after divergences have accumulated.
3. Match the QA workflow to document risk class. Administrative Module 1 content, patient-facing ICFs and safety-critical pharmacovigilance narratives each require a different QA treatment. Applying the same workflow to every document class wastes resource on low-risk content and under-protects high-risk content.
4. Embed translation into the submission timeline, not after it. Translation is a critical-path activity for every centralised procedure, with deliverables anchored to Day 120, Day 180 and Day 210 milestones. Treating it as a post-drafting task routinely creates unnecessary deadline pressure and surcharge cost.
5. Appoint a single linguistic project owner per procedure. A single point of accountability for terminology decisions, linguist briefing and inspector-ready documentation prevents the fragmentation that arises when translation is managed across multiple vendors or internal stakeholders.

How do you integrate translation into the submission timeline?

Integrate translation by mapping each deliverable to a specific regulatory milestone — IMPD ready at CTA submission, PIL and SmPC ready at EMA Day 180, IFU ready at MDR technical file lock, PSUR translation ready at the EURD list due date — and reserving linguist capacity in advance through a project capacity plan. Standard turnaround rates of three working days per 5,000 words allow precise backward scheduling from each milestone date, and a same-day capability for up to 10,000 words provides a contingency buffer for late-stage source amendments. Project management aligns linguist availability directly to the sponsor’s regulatory strategy calendar, so capacity is confirmed before it is needed rather than sourced reactively under deadline pressure.

How do you handle regulatory queries that require translation updates?

Handle a regulatory query by re-opening the affected TEP package, incrementing the translation memory version, re-issuing the amended segment within 48 hours and logging the change in the audit trail for the next inspection. The 48-hour SLA covers Day 120 and Day 180 EMA linguistic queries and MHRA deficiency responses, keeping the sponsor’s submission clock intact. Terminology sign-off for any amended term is documented in the same audit trail entry, so the inspector’s review of query-response correspondence has complete linguistic provenance from source amendment through to final translated output.